论文部分内容阅读
多年来,β受体阻滞剂是治疗肥厚性心肌病的主要药物,虽然该药通常有效,但并非对所有患者均有效,且有副作用。近年来异搏定已用于治疗肥厚性心肌病,本文旨在评价长期应用异搏定的临床效果。方法肥厚性心肌病78例中男38,女40例。年龄13～70(平均46)岁。其中梗阻型67例,非梗阻型7例,有4例曾施行过室间隔肌切开一肌部分切除术(myotomy-myectomy)。78例中心功能Ⅳ级6例,Ⅲ级56例(两者占总数79%);Ⅱ级15例;Ⅰ级1例,该例有频发室性早搏及室性心动过速。67例曾接受过心得安治疗,最大剂量为40～1,600mg/d,平均320mg/d。3例曾用甲氧乙心安治疗。异搏定治疗方法:开始时每6h 口服80mg,共8次,然后增至每
For many years, beta-blockers have been the mainstay of treatment for hypertrophic cardiomyopathy and although this is usually effective, it is not effective in all patients and has side effects. In recent years, verapamil has been used to treat hypertrophic cardiomyopathy, this article aims to evaluate the long-term clinical application of verapamil. Methods 78 cases of hypertrophic cardiomyopathy in 38 males and 40 females. Age 13 ~ 70 (average 46) years old. Among them, 67 were obstructive, 7 were non-obstructive, and 4 had myotomy-myectomy. 78 cases of center function grade 6 in 6 cases, grade Ⅲ 56 cases (both 79% of the total); Ⅱ grade in 15 cases; Ⅰ level in 1 case, this case of frequent premature ventricular contractions and ventricular tachycardia. 67 cases had received propranolol therapy, the maximum dose of 40 ~ 1,600 mg / d, an average of 320 mg / d. 3 cases had metoprolol treatment. Verapamil treatment: the beginning of every 6h oral 80mg, a total of 8 times, and then increased to each